BrePco Biopharma is pleased to announce that Neoatricon® - Dopamine Hydrochloridefor Infusion, is now available in Germany. About Neoatricon® Neoatricon® is a critical inotropic and vasopressor agent and is the only formulation of Dopamine Hydrochloride approved for the treatment of hypotension in Neonates, Infants and Children under 18 years of age. The availability of an age-appropriate formulation of …

May 2024 European Commission grants PUMA  COMMISSION IMPLEMENTING DECISION  of 27.5.2024 granting a paediatric use marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council and Regulation (EC) 1901/2006 of the European Parliament and of the Council for "Neoatricon - dopamine hydrochloride"

EMA/CHMP/61250/2024Committee for Medicinal Products for Human Use (CHMP) Summary of opinion1 (initial authorisation):“Neoatricon® dopamine hydrochloride: On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a paediatric use marketing authorisation (PUMA) for the medicinal product Neoatricon, intended for treatment of hypotension in neonates, infants and children …

Piramal Critical Care (PCC), a global leader in critical care medicines have acquired the EU, UK, Norway and South Africa  commercialization rights and will sell market and distribute  Neoatricon® in these countries. About BrePco Biopharma Limited: Ireland-based BPCO develops products for the unique needs of paediatric patients. The development of Neoatricon®  was part funded by the …